Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/30/2025

Juvenile Idiopathic Arthritis Management

Diagnosis and Initial Therapy

  • The American College of Rheumatology strongly recommends initial laboratory testing and disease-modifying antirheumatic drugs (DMARDs) for the diagnosis and treatment of juvenile idiopathic arthritis, with methotrexate being the preferred conventional DMARD for most JIA subtypes 1
  • Initial therapy with a DMARD is strongly recommended over NSAID monotherapy 1
  • Using methotrexate monotherapy as initial therapy is conditionally recommended over triple DMARD therapy 1
  • A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy 2

Medications

  • Intraarticular glucocorticoid injections are strongly recommended as part of initial therapy, with triamcinolone hexacetonide being strongly preferred over triamcinolone acetonide 1
  • Oral glucocorticoids are conditionally recommended against as part of initial therapy for oligoarticular JIA, but may be used as bridging therapy (<3 months) during initiation or escalation of therapy in patients with high or moderate disease activity 1
  • Conventional synthetic DMARDs are strongly recommended if inadequate response to NSAIDs and/or intraarticular glucocorticoids, with methotrexate being conditionally recommended as the preferred agent over leflunomide, sulfasalazine, and hydroxychloroquine 1, 2
  • Subcutaneous methotrexate is conditionally recommended over oral methotrexate 1
  • Use of folic/folinic acid in conjunction with methotrexate is strongly recommended 3
  • Combination therapy with a DMARD is strongly recommended for infliximab and conditionally recommended for other biologics 1

Monitoring and Adjustments

  • Laboratory monitoring should include:
  • Validated disease activity measures should be used to facilitate a treat-to-target approach, aiming for low disease activity (cJADAS-10 ≤2.5) or remission, with consideration of escalation of therapy if low disease activity is not achieved 1, 2
  • Dose adjustment is recommended if clinically relevant elevation in LFTs or decreased neutrophil/platelet count occurs, including:
  • Additional monitoring recommendations include:

Non-Pharmacologic Interventions

  • Physical and occupational therapy is conditionally recommended regardless of concomitant pharmacologic therapy 3
  • Discussion of healthy, age-appropriate diet is strongly recommended, while use of a specific diet to treat JIA is strongly recommended against 3

Vaccinations

  • Inactivated vaccines are recommended for all JIA patients, while live vaccines should be avoided in patients on biologic DMARDs